It is an azole antifungal drug indicated for use in the treatment of: ? Invasive aspergillosis ? Candidemia (nonneutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds ? Esophageal candidiasis ? Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy
Voriconazole is a triazole antifungal medication used to treat serious fungal infections. Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.
Adult: ?40 kg: 400 mg (10 mL) 12 hrly for the 1st 24 hr, followed by 200 mg (5 mL) 12 hrly, may increase to 300 mg 12 hrly or reduce by decrements of 50 mg if necessary. <40 kg: 200 mg (5 mL) 12 hrly for the 1st 24 hr, followed by 100 mg (2.5 mL) 12 hrly, may increase to 150 mg 12 hrly or reduce by decrements of 50 mg if necessary. For oesophageal candidiasis: Treatment should be given for at least 14 days and continued for 7 days after symptoms resolved. Child: 2-14 yr <50 kg: 9 mg/kg (Max: 350 mg) 12 hrly.
CYP3A4, CYP2C9 and CYP2C19 inhibitors and inducers: Adjust Voriconazole dosage and monitor for adverse reactions or lack of efficacy
Voriconazole may increase the concentrations and activity of drugs that are CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce doses of these other drugs and monitor for adverse reactions
Increase maintenance oral and intravenous dosage of Voriconazole with co-administration of Phenytoin or Efavirenz
? Hypersensitivity to voriconazole or its excipients ? Coadministration with terfenadine, astemizole, cisapride, pimozide or quinidine, sirolimus due to risk of serious adverse reactions ? Coadministration with rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John?s Wort due to risk of loss of efficacy
Visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, hallucinations
Pregnant women: Do not administer to pregnant women unless the benefit to the mother outweighs the risk to the fetus. Inform pregnant woman of risk . ? Nursing women: Discontinue It or discontinue nursing ? Pediatrics: Safety/effectiveness in patients <12 years has not been established
There is no data found about overdose of Voriconazole.
Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light. Store Voriconazole powder for suspension between 2° to 8°C temperature.
.png&w=384&q=75)